Myelodysplastic Syndromes synonyms

Myelodysplastic Syndromes (MDS) are a group of diverse bone marrow disorders characterized by the inefficient production of healthy blood cells. While "Myelodysplastic Syndromes" is the current clinical standard, you may encounter the older term "preleukemia" or "smoldering leukemia" in historical medical literature or older patient records.

What are the common synonyms and historical names for Myelodysplastic Syndromes?

In medical records, you may see Myelodysplastic Syndromes referred to by several names due to evolving diagnostic criteria. Historically, these conditions were often grouped under the umbrella of "preleukemia" because of the risk of progression to acute myeloid leukemia (AML). Other outdated or descriptive terms include "refractory anemia with excess blasts" (RAEB) or "dysmyelopoietic syndrome." While these specific subtypes remain important for classification, the overarching term Myelodysplastic Syndromes is now the universally preferred nomenclature in clinical oncology.

How are Myelodysplastic Syndromes classified in medical databases?

Official medical classification systems use specific codes to track Myelodysplastic Syndromes for research and insurance purposes. Understanding these codes can help you navigate your own medical records:

• ICD-10-CM: Classified under code D46, which encompasses various forms of Myelodysplastic Syndromes.


• Orphanet: Listed under ORPHA:597, providing a comprehensive overview of the condition's clinical spectrum.


• OMIM: While MDS is a clinical diagnosis, specific genetic mutations associated with Myelodysplastic Syndromes are cataloged under various entries, reflecting the disease's heterogeneous genetic origin.

Why do Myelodysplastic Syndromes have multiple names?

The nomenclature for Myelodysplastic Syndromes has shifted as our understanding of bone marrow failure has advanced. In the past, classification was based primarily on how cells appeared under a microscope (morphology). Today, classification relies on a combination of morphology, cytogenetics (chromosomal changes), and molecular testing. This shift from descriptive historical names like "smoldering leukemia" to the more precise Myelodysplastic Syndromes allows physicians to better predict disease progression and select targeted therapies for the 36 members of the DiseaseMaps community currently navigating this diagnosis.

Next steps

• Discuss your specific subtype of Myelodysplastic Syndromes with your hematologist to understand your unique prognosis.


• Request a copy of your pathology report to see how your specific diagnosis is coded.


• Connect with the 36 peers in the DiseaseMaps.org community to share experiences and coping strategies.


• Consult the NIH GARD website for the most recent clinical trial information.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Myelodysplastic syndromes


• Orphanet: Rare disease database (ORPHA:597)


• OMIM (Online Mendelian Inheritance in Man): Clinical entries for myeloid malignancies


• The Myelodysplastic Syndromes Foundation: Official patient education resources